Case Report
Published on 24 Jul 2025
Cadonilimab as second-line therapy in immunotherapy-resistant squamous NSCLC: a case report and review
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1627147
- 3,794 views